BeOne Medicines AG (HKG:6160)
Hong Kong
· Delayed Price · Currency is HKD 184.50
+5.60 (3.13%)
Mar 10, 2026, 2:54 PM HKT
BeOne Medicines AG Revenue
In the year 2025, BeOne Medicines AG had annual revenue of $5.34B USD with 40.23% growth. BeOne Medicines AG had revenue of $1.50B in the quarter ending December 31, 2025, with 32.84% growth.
Revenue
$5.34B
Revenue Growth
+40.23%
P/S Ratio
6.31
Revenue / Employee
$445.25K
Employees
12,000
Market Cap
262.26B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi Biologics | 21.98B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
| RemeGen | 3.62B |
| 3SBio | 9.94B |
| Shanghai Henlius Biotech | 6.35B |
BeOne Medicines AG News
- 12 days ago - BeiGene (ONC) Q4 Earnings Preview: Revenue Set for Growth - GuruFocus
- 11 months ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 1 year ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire